BAM
SPHS

Belpointe Asset Management’s Sophiris Bio, Inc. SPHS Stock Holding History

Belpointe Asset Management’s Portfolio SPHS Stock Details SPHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-38,050
Closed -$76K – 408
2018
Q1 		$76K Hold
38,050
– – 0.02% 337
2017
Q4 		$86K Buy
+38,050
New +$82.8K 0.02% 446

Other funds holding SPHS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BO
BRR OpCo Columbus, Ohio $814M AUM 9.75% 1-Year Est. Return
ACM
Alpha Capital Management Austin, Texas $690M AUM 22.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Belpointe Asset Management's SPHS Position: Q2 2018 in Review

Belpointe Asset Management sold out of Sophiris Bio, Inc. (SPHS) in Q2 2018, closing a stake of 38,050 shares — an estimated $76K sold.

Belpointe Asset Management first reported a position in SPHS in Q4 2017 and held it in 2 quarters. The position peaked at $86K in Q4 2017. 30 funds tracked by Wall St. Rank hold SPHS as of Q2 2018.

  • Belpointe Asset Management reported no remaining Sophiris Bio, Inc. position as of Q2 2018 after selling out during the quarter.
  • Belpointe Asset Management sold 38,050 Sophiris Bio, Inc. shares in Q2 2018, an estimated $76K.
  • Belpointe Asset Management first reported a position in Sophiris Bio, Inc. in Q4 2017 and held it in 2 quarters.
  • Belpointe Asset Management's Sophiris Bio, Inc. position peaked at $86K in Q4 2017.
  • 30 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q2 2018.

Based on Belpointe Asset Management's 13F filing for Q2 2018, filed 6 Aug 2018.